Stock Groups

Pasithea Therapeutics Stock Skyrockets On Nasal Spray Approval -Breaking

by Mike Robinson

[ad_1]

© Reuters.

Sam Boughedda

Investing.com — Shares Pasithea Therapeutics Corp (NASDAQ) shares shot up Tuesday following the news that Pasithea Clinics was approved by FDA to supply esketamine nasal Spray (SPRAVATO), which is used for treating adults suffering from treatment-resistant depressive disorder.

Pasithea shares jumped 220% to $7.08

The biotechnology firm, which focuses on treatments for psychiatric and neurological disorders, said it has started offering the treatment in its Knightsbridge, London, location — becoming only one of three clinics in the U.K. approved to provide the treatment.

Pasithea CEO Tiago Reis Martques called this approval “important” for the U.K. clinics as well as their patients.

Pasithea Clinics launched an intravenous therapy using ketamine last week for those suffering from similar mental disorders. 

Disclaimer: Fusion MediaWe remind you that this site does not contain accurate or real-time data. CFDs are stocks, indexes or futures. The prices of Forex and CFDs are not supplied by exchanges. They are instead provided by market makers. As such, the prices might not reflect market values and could be incorrect. Fusion Media is not responsible for trading losses that may be incurred as a consequence of the use of this data.

Fusion MediaFusion Media and anyone associated with it will not assume any responsibility for losses or damages arising from the use of this website’s data including quotes, charts, or buy/sell signal information. You should be aware of the potential risks and financial costs involved in trading the financial market. It is among the most risky forms of investment.

[ad_2]